Elder  Granger net worth and biography

Elder Granger Biography and Net Worth

Director of Better Therapeutics

General Elder Granger, age 67 years, is a U.S. Army Major General (Retired) and has served as the President and Chief Executive Officer of THE 5Ps, LLC, a healthcare, education, and leadership consulting firm, since August 2009. He served in the U.S. Army for over 35 years before retiring in June 2009 and was the Deputy Director and Program Executive Officer of TRICARE Management Activity, Office of the Assistant Secretary of Defense (Health Affairs) in Washington, D.C. from December 2005 to June 2009. He is board certified by the American College of Physician Executives, American College of Healthcare Executives, American Board of Medical Quality, and American Board of Internal Medicine, National Association of Corporate Directors, and holds numerous medical certifications. General Granger currently serves on the board of directors of Cigna Corporation (since 2018), Cerner Corporation (since 2020) and DLH Holdings Corp (since 2014), and he previously served on the board of directors of Express Scripts Holding Company (from 2015 to 2018). He received his Bachelor of Science Degree from Arkansas State University in 1976 and earned his medical degree from University of Arkansas School of Medicine in 1980.

General Granger has extensive experience in health care management and operations, including health policy, planning, budgeting, compliance, and execution related to the health program for uniformed service members around the globe. General Granger has unique leadership and policy experience through his career with the U.S. Army and the commercial sector.

What is Elder Granger's net worth?

The estimated net worth of Elder Granger is at least $0.00 as of June 17th, 2024. Dr. Granger owns 5,471 shares of Better Therapeutics stock worth more than $0 as of November 21st. This net worth approximation does not reflect any other investments that Dr. Granger may own. Learn More about Elder Granger's net worth.

How do I contact Elder Granger?

The corporate mailing address for Dr. Granger and other Better Therapeutics executives is 311 WEST 43RD STREET 12TH FLOOR, NEW YORK NY, 10036. Better Therapeutics can also be reached via phone at 415-887-2311 and via email at [email protected]. Learn More on Elder Granger's contact information.

Has Elder Granger been buying or selling shares of Better Therapeutics?

Elder Granger has not been actively trading shares of Better Therapeutics during the past quarter. Most recently, on Tuesday, May 16th, Elder Granger bought 600 shares of Better Therapeutics stock. The stock was acquired at an average cost of $0.87 per share, with a total value of $522.00. Following the completion of the transaction, the director now directly owns 1,600 shares of the company's stock, valued at $1,392. Learn More on Elder Granger's trading history.

Who are Better Therapeutics' active insiders?

Better Therapeutics' insider roster includes Kevin Appelbaum (CEO), Andrew Armanino (Director), Elder Granger (Director), Mark Heinen (Insider), and Risa Lavizzo-Mourey (Director). Learn More on Better Therapeutics' active insiders.

Elder Granger Insider Trading History at Better Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2023Buy600$0.87$522.001,600View SEC Filing Icon  
12/3/2021Buy1,000$6.66$6,660.00View SEC Filing Icon  
See Full Table

Elder Granger Buying and Selling Activity at Better Therapeutics

This chart shows Elder Granger's buying and selling at Better Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Better Therapeutics Company Overview

Better Therapeutics logo
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

2 Week Range

Now: N/A

Volume

2,000 shs

Average Volume

2,449,991 shs

Market Capitalization

$5,000.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89